Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet (扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial
Background Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (扶正化瘀片, FZHY), have an antifibrotic effect in patients with CHB. Objective To observe the safety and effi...
Saved in:
| Published in | Chinese journal of integrative medicine Vol. 27; no. 7; pp. 509 - 513 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Singapore
Springer Singapore
01.07.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-0415 1993-0402 1993-0402 |
| DOI | 10.1007/s11655-020-3257-6 |
Cover
| Abstract | Background
Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (扶正化瘀片, FZHY), have an antifibrotic effect in patients with CHB.
Objective
To observe the safety and efficacy of adjunctive FZHY in patients with hepatitis B virus (HBV) cirrhosis, this study was designed as a randomized, placebo-controlled, double-blind, parallel assignment, multicenter trial at 20 centers in China. The total 700 naive patients will be enrolled with compensate cirrhosis due to HBV, and randomly assigned into 2 groups, receiving entecavir (0.5 mg, daily) and FZHY placebo (1.6 g, 3 times a day), or entecavir (0.5 mg, daily) and FZHY (1.6 g, 3 times a day), respectively. The primary endpoint was histological improvement at week 48. The secondary outcome is the decline values of liver fibrosis using the noninvasive methods from baseline to week 48 in each arm of the study. Adverse events such as stomach upset, headache, fatigue, dizziness, nausea will be strictly recorded.
Discussion
Through this study, we hope to generate a solid evidence for the therapeutic strategy of HBV cirrhosis with a combination of anti-viral such as ETV and anti-fibrotic herbal product such as FZHY. Protocol version: Version 1.3, Date: 2014.12.4. Trial registration number: NCT02241590. |
|---|---|
| AbstractList | Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.BACKGROUNDAntiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.To observe the safety and efficacy of adjunctive FZHY in patients with hepatitis B virus (HBV) cirrhosis, this study was designed as a randomized, placebo-controlled, double-blind, parallel assignment, multicenter trial at 20 centers in China. The total 700 naive patients will be enrolled with compensate cirrhosis due to HBV, and randomly assigned into 2 groups, receiving entecavir (0.5 mg, daily) and FZHY placebo (1.6 g, 3 times a day), or entecavir (0.5 mg, daily) and FZHY (1.6 g, 3 times a day), respectively. The primary endpoint was histological improvement at week 48. The secondary outcome is the decline values of liver fibrosis using the noninvasive methods from baseline to week 48 in each arm of the study. Adverse events such as stomach upset, headache, fatigue, dizziness, nausea will be strictly recorded.OBJECTIVETo observe the safety and efficacy of adjunctive FZHY in patients with hepatitis B virus (HBV) cirrhosis, this study was designed as a randomized, placebo-controlled, double-blind, parallel assignment, multicenter trial at 20 centers in China. The total 700 naive patients will be enrolled with compensate cirrhosis due to HBV, and randomly assigned into 2 groups, receiving entecavir (0.5 mg, daily) and FZHY placebo (1.6 g, 3 times a day), or entecavir (0.5 mg, daily) and FZHY (1.6 g, 3 times a day), respectively. The primary endpoint was histological improvement at week 48. The secondary outcome is the decline values of liver fibrosis using the noninvasive methods from baseline to week 48 in each arm of the study. Adverse events such as stomach upset, headache, fatigue, dizziness, nausea will be strictly recorded.Through this study, we hope to generate a solid evidence for the therapeutic strategy of HBV cirrhosis with a combination of anti-viral such as ETV and anti-fibrotic herbal product such as FZHY. Protocol version: Version 1.3, Date: 2014.12.4.DISCUSSIONThrough this study, we hope to generate a solid evidence for the therapeutic strategy of HBV cirrhosis with a combination of anti-viral such as ETV and anti-fibrotic herbal product such as FZHY. Protocol version: Version 1.3, Date: 2014.12.4.NCT02241590.TRIAL REGISTRATION NUMBERNCT02241590. Background Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (扶正化瘀片, FZHY), have an antifibrotic effect in patients with CHB. Objective To observe the safety and efficacy of adjunctive FZHY in patients with hepatitis B virus (HBV) cirrhosis, this study was designed as a randomized, placebo-controlled, double-blind, parallel assignment, multicenter trial at 20 centers in China. The total 700 naive patients will be enrolled with compensate cirrhosis due to HBV, and randomly assigned into 2 groups, receiving entecavir (0.5 mg, daily) and FZHY placebo (1.6 g, 3 times a day), or entecavir (0.5 mg, daily) and FZHY (1.6 g, 3 times a day), respectively. The primary endpoint was histological improvement at week 48. The secondary outcome is the decline values of liver fibrosis using the noninvasive methods from baseline to week 48 in each arm of the study. Adverse events such as stomach upset, headache, fatigue, dizziness, nausea will be strictly recorded. Discussion Through this study, we hope to generate a solid evidence for the therapeutic strategy of HBV cirrhosis with a combination of anti-viral such as ETV and anti-fibrotic herbal product such as FZHY. Protocol version: Version 1.3, Date: 2014.12.4. Trial registration number: NCT02241590. |
| Author | Zheng, Qing-shan Liu, Cheng-hai Li, Zheng-xin Zhao, Zhi-min Liu, Ping |
| Author_xml | – sequence: 1 givenname: Zheng-xin surname: Li fullname: Li, Zheng-xin organization: Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine – sequence: 2 givenname: Zhi-min surname: Zhao fullname: Zhao, Zhi-min organization: Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine – sequence: 3 givenname: Ping surname: Liu fullname: Liu, Ping organization: Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine – sequence: 4 givenname: Qing-shan surname: Zheng fullname: Zheng, Qing-shan organization: Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine – sequence: 5 givenname: Cheng-hai surname: Liu fullname: Liu, Cheng-hai email: chenghai.liu@outlook.com organization: Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine |
| BookMark | eNp9kbFuFDEQhlcoSCSBB6BzGSQWbO_a3qMjl4SLFARCB63ltWfvHPnsYHuDkooORaJG6VPT8kYkr4GPo6JINTOa-f4Zzb9TbfngoaqeEvyCYCxeJkI4YzWmuG4oEzV_UG2TyaSpcYvpVsm5oCUn7FG1k9IpxkxwzLarm3kElVfgMwoDmu1_QlMb4zIkm9AXm5foaLxcgl-g2aguRjRXvYOM9m6vft3-vPn9_cfd9de7q2_PkPIGHfoMWp3b-AodQLILv5ZU6EPphZW9BPMcHYSxCNT7zvpSvVdROQfuL_12dNnqcghENC19q5VD82iVe1w9HJRL8ORf3K0-Hh3Op7P65N2b4-nrk1rThvO6Y7onosWGDu3Q9xM98HagwmAjoAPVTbgxhHQMemIGMrSkM0x0gjVE9Bpa3exWexvdsxg-j5CyXNmkwTnlIYxJ0pZwKhre0TJKNqM6hpQiDPIs2pWKF5JguTZEbgyRxRC5NkTywoj_GG2zyjb4HJV195J0Q6ayxS8gytMwRl9-cQ_0B3Kxp0g |
| CitedBy_id | crossref_primary_10_1016_S1875_5364_23_60443_1 crossref_primary_10_3389_fcimb_2023_1273031 crossref_primary_10_1016_j_heliyon_2023_e22216 crossref_primary_10_3389_fphar_2022_942841 crossref_primary_10_4254_wjh_v15_i9_1043 crossref_primary_10_1016_j_jep_2023_116419 crossref_primary_10_1155_2022_5752803 crossref_primary_10_3389_fphar_2023_1329266 |
| Cites_doi | 10.1007/s12072-015-9675-4 10.3748/wjg.v11.i19.2892 10.1002/hep.23424 10.4254/wjh.v7.i22.2404 10.1016/S0140-6736(12)61425-1 10.1016/S0016-5085(14)60921-5 10.1111/jgh.12718 10.1056/NEJMoa051285 10.1080/17843286.2015.1118183 10.1002/hep.23785 10.3736/jcim20120512 10.1016/0168-8278(95)80226-6 10.1186/1749-8546-4-12 |
| ContentType | Journal Article |
| Copyright | The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature. |
| Copyright_xml | – notice: The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020 – notice: 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature. |
| DBID | AAYXX CITATION 7X8 |
| DOI | 10.1007/s11655-020-3257-6 |
| DatabaseName | CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1993-0402 |
| EndPage | 513 |
| ExternalDocumentID | 10_1007_s11655_020_3257_6 |
| GroupedDBID | --- -5E -5G -BR -EM -SE -S~ -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 29B 29~ 2B. 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 36B 4.4 406 408 40D 40E 5GY 5VR 5VS 6NX 6PF 92F 92I 93N 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAXDM AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACSNA ACUDM ACZOJ ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFUIB AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BGNMA CAG CAJEE CCEZO CHBEP CIEJG COF CS3 CSCUP CW9 DDRTE DNIVK DPUIP DU5 EBLON EBS EIOEI EJD EMB EMOBN ESBYG F5P FA0 FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ ITM IWAJR I~X I~Z J-C JBSCW JZLTJ LLZTM M4Y MA- NDZJH NPVJJ NQJWS NU0 O9- P9S PF0 PT4 Q-- QOR QOS R89 R9I ROL RPX RSV S16 S1Z S26 S27 S28 S37 S3B SAP SCL SCLPG SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SV3 SZ9 SZN T13 T16 TCJ TGQ TSG TT1 TUC U1G U2A U5O U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WFFXF WK8 YLTOR Z7U ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION 7X8 |
| ID | FETCH-LOGICAL-c2366-85cb1740d2f4fbb9cf64f27d0d7e8ea896dd1185eb1df1f418d57875317bce4c3 |
| IEDL.DBID | U2A |
| ISSN | 1672-0415 1993-0402 |
| IngestDate | Wed Oct 01 12:55:32 EDT 2025 Wed Oct 01 01:53:48 EDT 2025 Thu Apr 24 23:08:45 EDT 2025 Fri Feb 21 02:48:18 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | chronic hepatitis B Fuzheng Huayu Tablet liver fibrosis trial protocol randomized multicenter trial |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2366-85cb1740d2f4fbb9cf64f27d0d7e8ea896dd1185eb1df1f418d57875317bce4c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PQID | 2416273682 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2416273682 crossref_primary_10_1007_s11655_020_3257_6 crossref_citationtrail_10_1007_s11655_020_3257_6 springer_journals_10_1007_s11655_020_3257_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20210700 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 7 year: 2021 text: 20210700 |
| PublicationDecade | 2020 |
| PublicationPlace | Singapore |
| PublicationPlace_xml | – name: Singapore |
| PublicationTitle | Chinese journal of integrative medicine |
| PublicationTitleAbbrev | Chin. J. Integr. Med |
| PublicationYear | 2021 |
| Publisher | Springer Singapore |
| Publisher_xml | – name: Springer Singapore |
| References | Ishak, Baptista, Bianchi, Callea, De Groote, Gudat (CR12) 1995; 22 Liu, Hu, Xu, Liu, Liu (CR14) 2009; 4 Liu, Hu, Liu (CR9) 2005; 11 Jia, Li (CR11) 2010; 27 Marcellin, Gane, Buti, Afdhal, Sievert, Jacobson (CR7) 2013; 381 Chang, Gish, de Man, Gadano, Sollano, Chao (CR5) 2010; 52 Wu, Lai, Han, Han, Gordon, Chao (CR4) 2010; 51 Hassanein, Box, Tong, Pozza, Rossaro (CR10) 2014; 146 Chang, Gish, de Man, Gadano, Sollano, Chao (CR6) 2006; 354 Honda, Seike, Murakami (CR2) 2015; 7 Xu, Lin, Xu, Zhuang, Guo, Liu (CR8) 2015; 30 Kose, Tatar, Gul, Pala (CR3) 2016; 71 Wang, Tao, Shen, Cui, Liu (CR13) 2012; 10 Sarin, Kumar, Lau, Abbas, Chan, Chen (CR1) 2016; 10 B Xu (3257_CR8) 2015; 30 TT Chang (3257_CR6) 2006; 354 T Hassanein (3257_CR10) 2014; 146 JD Jia (3257_CR11) 2010; 27 P Marcellin (3257_CR7) 2013; 381 S Kose (3257_CR3) 2016; 71 K Honda (3257_CR2) 2015; 7 QL Wang (3257_CR13) 2012; 10 K Ishak (3257_CR12) 1995; 22 IC Wu (3257_CR4) 2010; 51 CH Liu (3257_CR14) 2009; 4 TT Chang (3257_CR5) 2010; 52 SK Sarin (3257_CR1) 2016; 10 P Liu (3257_CR9) 2005; 11 |
| References_xml | – volume: 10 start-page: 1 year: 2016 end-page: 98 ident: CR1 article-title: Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update publication-title: Hepatol Int doi: 10.1007/s12072-015-9675-4 – volume: 11 start-page: 2892 year: 2005 end-page: 2899 ident: CR9 article-title: Multicenter clinical study on Fuzheng Huayu Capsule against liver fibrosis due to chronic hepatitis B publication-title: World J Gastroenterol doi: 10.3748/wjg.v11.i19.2892 – volume: 51 start-page: 1185 year: 2010 end-page: 1189 ident: CR4 article-title: Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage publication-title: Hepatology doi: 10.1002/hep.23424 – volume: 7 start-page: 2404 year: 2015 end-page: 2410 ident: CR2 article-title: Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis publication-title: World J Hepatol doi: 10.4254/wjh.v7.i22.2404 – volume: 381 start-page: 468 year: 2013 end-page: 475 ident: CR7 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 – volume: 146 start-page: S261 year: 2014 ident: CR10 article-title: A phase E, randomized, placebo-controlled, double-blind, multi-center study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis (S-USIIT-01) publication-title: Gastroenterology doi: 10.1016/S0016-5085(14)60921-5 – volume: 30 start-page: 372 year: 2015 end-page: 378 ident: CR8 article-title: Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12718 – volume: 27 start-page: 113 year: 2010 end-page: 128 ident: CR11 article-title: Guideline of prevention and treatment for chronic hepatitis B (2010) publication-title: J Clin Hepatol (Chin) – volume: 354 start-page: 1001 year: 2006 end-page: 1010 ident: CR6 article-title: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B publication-title: N Engl J Med doi: 10.1056/NEJMoa051285 – volume: 71 start-page: 244 year: 2016 end-page: 249 ident: CR3 article-title: The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B publication-title: Acta Clin Belg doi: 10.1080/17843286.2015.1118183 – volume: 52 start-page: 886 year: 2010 end-page: 893 ident: CR5 article-title: Long-term entecavir therapy results in the reversal of fibrosis/ cirrhosis and continued histological improvement in patients with chronic hepatitis B publication-title: Hepatology doi: 10.1002/hep.23785 – volume: 10 start-page: 561 year: 2012 end-page: 568 ident: CR13 article-title: Chinese herbal medicine Fuzheng Huayu Recipe inhibits liver fibrosis by mediating the transforming growth factor-beta1/Smads signaling pathway publication-title: J Chin Integr Med (Chin) doi: 10.3736/jcim20120512 – volume: 22 start-page: 696 year: 1995 end-page: 699 ident: CR12 article-title: Histological grading and staging of chronic hepatitis publication-title: J Hepatol doi: 10.1016/0168-8278(95)80226-6 – volume: 4 start-page: 12 year: 2009 ident: CR14 article-title: Effect of Fuzheng Huayu Formula and its actions against liver fibrosis publication-title: Chin Med doi: 10.1186/1749-8546-4-12 – volume: 10 start-page: 1 year: 2016 ident: 3257_CR1 publication-title: Hepatol Int doi: 10.1007/s12072-015-9675-4 – volume: 30 start-page: 372 year: 2015 ident: 3257_CR8 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12718 – volume: 381 start-page: 468 year: 2013 ident: 3257_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 – volume: 10 start-page: 561 year: 2012 ident: 3257_CR13 publication-title: J Chin Integr Med (Chin) doi: 10.3736/jcim20120512 – volume: 146 start-page: S261 year: 2014 ident: 3257_CR10 publication-title: Gastroenterology doi: 10.1016/S0016-5085(14)60921-5 – volume: 52 start-page: 886 year: 2010 ident: 3257_CR5 publication-title: Hepatology doi: 10.1002/hep.23785 – volume: 354 start-page: 1001 year: 2006 ident: 3257_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa051285 – volume: 4 start-page: 12 year: 2009 ident: 3257_CR14 publication-title: Chin Med doi: 10.1186/1749-8546-4-12 – volume: 71 start-page: 244 year: 2016 ident: 3257_CR3 publication-title: Acta Clin Belg doi: 10.1080/17843286.2015.1118183 – volume: 27 start-page: 113 year: 2010 ident: 3257_CR11 publication-title: J Clin Hepatol (Chin) – volume: 7 start-page: 2404 year: 2015 ident: 3257_CR2 publication-title: World J Hepatol doi: 10.4254/wjh.v7.i22.2404 – volume: 22 start-page: 696 year: 1995 ident: 3257_CR12 publication-title: J Hepatol doi: 10.1016/0168-8278(95)80226-6 – volume: 51 start-page: 1185 year: 2010 ident: 3257_CR4 publication-title: Hepatology doi: 10.1002/hep.23424 – volume: 11 start-page: 2892 year: 2005 ident: 3257_CR9 publication-title: World J Gastroenterol doi: 10.3748/wjg.v11.i19.2892 |
| SSID | ssj0057605 |
| Score | 2.284203 |
| Snippet | Background
Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines... Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB), but it has a limited effect on cirrhosis. Chinese medicines (CMs),... |
| SourceID | proquest crossref springer |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 509 |
| SubjectTerms | Medicine Medicine & Public Health Original Article |
| Title | Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet (扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial |
| URI | https://link.springer.com/article/10.1007/s11655-020-3257-6 https://www.proquest.com/docview/2416273682 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1993-0402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1993-0402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1993-0402 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057605 issn: 1672-0415 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9RAEG50F8SL-MTxsZTgwVfDpJPuJN5m1x0HZUVkRtZT6PTDHRgTSSaCe_ImC57F-569-o_c_RtWZRMHRQWPobvr0PXor1NfVTN2W2iLOCJIeOxdzCNlh1xLZzje24ywOgxlThfFnWdqMoue7Mrdro677tnufUqyjdSrYrdASaomxriBdsbVabYuqZsXGvFMjPrwi_i55S0GKhac6s_7VOafRPx6GK0Q5m9J0fasGZ9n5zqQCKMTrV5gp1xxkZ3Z6dLgl9jhtKeHQ-lhsvkStuZVtVfW8xroxyqMm_09V7yGSaPfNzCl8qgl3Dk6-Hb09fD7p8_HXz4cH3y8C7qwQKwAo9_Nq4fwqGVzkEgNL3CsfDPfd_YBIMhGAXwTdw2_nuuK3l9ZtKvb-l0ieLoKuhajC5iSUV9ms_H2dGvCu9cWuBGhUjyRJsfrydAKH_k8T41XkRexHdrYJU4nqbIWlSoxuFsf-ChILHk7-nCcGxeZ8ApbK8rCXWWATu6Ek6FLQx1FwqfUpt6nqQ4SZ5S0Azbstz0zXStyehFjka2aKJOmMtRURprK1IDd-7nk7Ukfjn9NvtXrMkNvoRSILlzZ1BniFYWATSViwO73Ss46t63_LvHaf82-zs4Kor60rN4bbG1ZNe4mYpdlvsHWR49fPd3eaG32B1LF67w |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgKwEX3ojlaSQOvFxtnMRJuLWlS6DdCqEUlZPl-EFXLAlKNkjsiRuqxBlx75kr_4j2bzDOxqyoAKnHKPYotsfjbzLfjBG6S4UCHOHFJDI6IgFTAyJCLQn4bZIq4fthbh3F0RZLt4PnO-FOl8ddO7a7C0m2lnqR7Oax0GYTg90APSPsJFoKwD-hPbS08vT1xrozwICgW-aixyJKbAa6C2b-Tcifx9ECYx4Ji7anzfAcytx3zkkmb5ebab4sZ0dKOB5zIOfR2Q594pW5ulxAJ3RxEZ0adfH1S2g_c7xzXBqcrr7Ca-Oq2i3rcY3tH1s8bGa7uniD00Z8bHBm866m-N7B3o-D7_s_v3w9_PbpcO_zfSwKhS3dQIoP4-oxftLSRKxIgV_Cu_LdeKbVIwzoHQSQVRgFPL0Qlb3YZdL2bhODLXNUV7irXTrBmd0tl9H2cD1bS0l3jQOR1GeMxKHMwe8ZKGoCk-eJNCwwNFIDFelYizhhSoG2hHBqKOMZWFNlzQgYhyiXOpD-FdQrykJfRRish6Y69HXiiyCgJrH1702SCC_WkoWqjwZuNbnsapzbqzYmfFGd2U4-h8nndvI566MHv7u8nxf4-F_jO05FOGxDG1sRhS6bmgMQYoAEWUz76KFbdt7Zg_rfEq8dq_VtdDrNRpt889nWxnV0hlp-TUsdvoF606rRNwEgTfNb3Yb4BeuQCeU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXVF5ioYCROPCyunEcJ-HWB6vl0apCu6g3y_GjXWlJqmSDRE_cUCXOiHvPXPlHtH-DmWzCCgRIHCPbc_DM2J8z38wQcp9rCzgiSFjsXcyEtH2mI2cYvNsMtzoMowwfits7cjgWL_aivbbPadWx3buQ5DynAas05bO1Q-vXFolvgYwwsxjOELA5Js-TCwLrJIBBj_l6dxQDlm44jIGMOcNc9C6s-ScRv15MC7T5W4C0uXcGK-RSCxjp-lzDl8k5l18hy9ttSPwqORl1VHFaeDrceEM3J2V5UFSTiuJPVjqojw5cvk-HtX5f0xGmSs3og9Pjb6dfT75_-nz25cPZ8ceHVOeWIkPA6HeT8indapgdKFLT1zBWvJ0cOfuEAuAGAWwDdhC-dnWJvVimzeomlxfJnq6kbbnRKR2hgV8j48Gz0eaQtZ0XmOGhlCyJTAZPlb7lXvgsS42XwvPY9m3sEqeTVFoLCo7goLc-8CJILHo--HOcGSdMeJ0s5UXubhAKDu-4i0KXhloI7lMsWe_TVAeJMzKyPdLvtl2Ztiw5dseYqkVBZdSUAk0p1JSSPfLo55LDeU2Of02-1-lSgedgOETnrqgrBdhFAniTCe-Rx52SVevC1d8l3vyv2XfJ8u7WQL16vvPyFrnIkRHTkH1XydKsrN1tgDSz7E5jtj8Ah1PxUA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+HBV+Cirrhosis+with+Fuzheng+Huayu+Tablet+%28%29+and+Entecavir%3A+Design+of+a+Randomized%2C+Double-Blind%2C+Parallel+and+Multicenter+Clinical+Trial&rft.jtitle=Chinese+journal+of+integrative+medicine&rft.au=Li%2C+Zheng-Xin&rft.au=Zhao%2C+Zhi-Min&rft.au=Liu%2C+Ping&rft.au=Zheng%2C+Qing-Shan&rft.date=2021-07-01&rft.issn=1993-0402&rft.eissn=1993-0402&rft.volume=27&rft.issue=7&rft.spage=509&rft_id=info:doi/10.1007%2Fs11655-020-3257-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1672-0415&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1672-0415&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1672-0415&client=summon |